Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jason Wuttke

Child & Adolescent Psychiatry New Orleans, LA Medical Doctor

NPI 1114942083 CMS profile 680119

1514 Jefferson Hwy, New Orleans, LA 70121

Open in the dashboard

General payments

$10,719

589 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jason Wuttke of New Orleans, LA is reported in the CMS Open Payments database as having received $10,719 across 589 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,174 117
2024 General $2,016 105
2023 General $2,099 114
2022 General $1,289 72
2021 General $1,039 58
2020 General $676 45
2019 General $1,426 78

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jason Wuttke
  • Child & Adolescent Psychiatry median
  • Middle half of Child & Adolescent Psychiatry
  • National median

In program year 2025, general payments to Jason Wuttke were reported at $2,174. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.

Show as a table
Year Jason Wuttke Child & Adolescent Psychiatry median Middle half National median
2019 $1,426 $129 $42–$419 $163
2020 $676 $81 $28–$226 $114
2021 $1,039 $115 $31–$326 $132
2022 $1,289 $124 $40–$382 $149
2023 $2,099 $130 $45–$420 $160
2024 $2,016 $141 $42–$490 $164
2025 $2,174 $132 $41–$474 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,275 79 payments
  2. Tris Pharma Inc $1,243 66 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $1,005 51 payments
  4. Ironshore Pharmaceuticals Inc. $882 44 payments
  5. Corium, Inc. $682 38 payments
  6. Supernus Pharmaceuticals, Inc. $676 30 payments
  7. Noven Therapeutics, LLC $672 38 payments
  8. Otsuka America Pharmaceutical, Inc. $658 36 payments
  9. ITI, Inc. $617 34 payments
  10. Janssen Pharmaceuticals, Inc $559 27 payments
  11. Other $2,450 146 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,680 588 payments
  2. Education $39 1 payment
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $934 57 payments
  2. VRAYLAR Neuroscience $731 53 payments
  3. Azstarys $682 38 payments
  4. REXULTI $658 36 payments
  5. Xelstrym $654 37 payments
  6. TRINTELLIX $633 32 payments
  7. Dyanavel XR $616 33 payments
  8. SPRAVATO $508 24 payments
  9. JORNAY PM $497 25 payments
  10. CAPLYTA $468 27 payments
  11. Other $4,796 247 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

585

Median for Neuropsychiatry: 88

Drug cost

$87,402

Median for Neuropsychiatry: $2,689

Branded share of claims

37.4%

Median for Neuropsychiatry: 16.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Sustenna Paliperidone Palmitate Brand 13 $29,275
Caplyta Lumateperone Tosylate Brand 18 $26,182
Auvelity Dextromethorphan Hbr/Bupropion Brand 11 $11,714
Jornay Pm Methylphenidate Hcl Brand 12 $5,321
Lamictal Lamotrigine Brand 12 $4,223
Duloxetine Hcl Generic 33 $1,940
Oxcarbazepine Generic 19 $1,381
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 37 $1,236
Aripiprazole Generic 25 $1,055
Vilazodone Hcl Generic 12 $982

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,891 Part D prescribers listed as Neuropsychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $306
$306 — —
JORNAY PM
  • Ironshore Pharmaceuticals Inc. $279
$279 12 —
Xelstrym
  • Noven Therapeutics, LLC $266
$266 — —
CAPLYTA
  • ITI, Inc. $196
$196 18 —
Dyanavel XR
  • Tris Pharma Inc $162
$162 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

589 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Child & Adolescent Psychiatry in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record